Breethe Funding: How Much Did They Raise & Key Investors

How Much Did Breethe Raise?
Funding & Key Investors

Breethe, Inc. has successfully secured a significant capital injection, bringing its total funding to $4.1M. This latest major strategic investment of $3M underscores the market confidence in the company's mission to revolutionize respiratory care. By focusing on the development of advanced medical hardware, the firm is positioning itself as a critical player in the life-sciences sector, aiming to address the severe limitations currently faced by clinicians treating end-stage lung failure.

The trajectory of this financing reflects a robust growth phase, moving from initial private equity backing to a more substantial enterprise-level capitalization. This influx of resources is earmarked to accelerate the clinical validation and product development cycles necessary to bring their compact artificial lung technology to the forefront of modern medicine.

What is Breethe?

Breethe

Manufacturing

Medical Devices & Equipment

Business Services

Breethe, Inc. operates at the intersection of cardiothoracic surgery and fluid mechanics, specializing in the creation of portable extracorporeal membrane oxygenation (ECMO) systems. The company was founded by Dr. Bartley Griffith, a luminary in the field, to solve the systemic failures in current lung support treatments. By engineering a compact, efficient artificial lung, Breethe aims to provide a viable bridge to recovery or transplant for patients suffering from acute and chronic respiratory conditions. Their market position is defined by a commitment to improving patient outcomes and rehabilitation efficacy, addressing a critical gap in the healthcare landscape where traditional options often fall short of providing the necessary support for long-term healing.

How much funding has Breethe raised?

Breethe has raised a total of $4.1M across 2 funding rounds:

2017

Private Equity

$1.1M

Private Equity

$3M

Private Equity (2017): $1.1M, investors not publicly disclosed

Private Equity (2017): $3M, investors not publicly disclosed

Key Investors in Breethe

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

Undisclosed Investor

Undisclosed investor participating in the funding round.

What's next for Breethe?

With the recent infusion of capital, Breethe is poised to transition from a research-heavy startup into a clinical-stage enterprise. The strategic roadmap likely involves rigorous regulatory navigation and the scaling of manufacturing capabilities to meet the high demand for portable respiratory support. As the company advances, the focus will shift toward integrating their technology into standard clinical workflows, thereby establishing a new benchmark for the treatment of lung failure. Investors and industry stakeholders are closely monitoring the firm's progress, as the successful deployment of this device could fundamentally alter the prognosis for hundreds of thousands of patients annually, marking a significant milestone in medical device innovation.

See full Breethe company page

See More Financial Insights